BMY stock downgraded at Raymond James after Turning Point acquisition (NYSE:BMY)
seekingalpha.com
science
2022-06-03 15:35:19

Drew Angerer/Getty Images News Raymond James has lowered its rating on Bristol Myers Squibb (NYSE:BMY) to Market Perform from Outperform on Friday after the pharma giant agreed to acquire the clinical-stage oncology biotech Turning Point Therapeutics (TPTX) for $4.1B in cash. The analyst Dane Leone highlights the potentially limited market opportunity for Turning Point's (TPTX) lead drug candidate, repotrectinib, a tyrosine kinase inhibitor targeted at ROS1 and NTRK oncogenic drivers of non-small cell lung cancer (NSCLC).
